SUBJ: Paxlovid in 2024 at $1390 for the 5 day course

SUBtitle: Calcium channel blockers increase risk of glaucoma

Useful links for new readers: how to get newsletter, links to nutritionconsensus.org/products; whyweage; 46steps to slow aging;  Key word search command

See past newsletters here    Please sponsor for $5/month here

SHORT NOTES: Pfizer has said it will price Paxlovid in 2024 at $1390 for the 5 day course when the government supply runs out. Nearly 6 million Americans have taken Paxlovid for free, courtesy of the federal government.

Calcium channel blockers increase risk of glaucoma by diminishing thickness of the macular ganglion cell complex. Amlodipine has the largest effect. Macular degeneration, cataracts, & diabetic retinopathy are other major causes of blindness in the elderly. (Take AREDsII to reduce risk of cataracts)

A faulty ubiquitin system leads to the accumulation of toxic proteins and amyloid plaque in Alzheimer’s patients. (Note Mito-C is designed to reduce misfolded proteins.)

The Lifespan newsletter is a good source of articles.

LONG NOTES:

Paxlovid has been free in 2022 & 2023 courtesy of the U.S. government. Pfizer has said it will price Paxlovid in 2024 at $1390 for the 5 day course when the government supply runs out. The U.S. government has so far purchased 20 million courses of Paxlovid, priced at ~$530 each, a discount for buying in bulk.
Nearly 6 million Americans have taken Paxlovid for free, courtesy of the federal government.

Calcium channel blockers increase risk of glaucoma (hazard ratio=1.4) by diminishing thickness of the macular ganglion cell complex. Amlodipine has the largest effect. Although most forms of open-angle glaucoma are due to an elevation of intraocular pressure, calcium channel blockers do not increase intraocular pressure.  Open-angle glaucoma is the most common form of glaucoma. It accounts for 9-12% of blindness in the U.S. and 19% of blindness in African Americans. A 200% increase in cases is expected by 2050. Macular degeneration, cataracts, & diabetic retinopathy are other major causes of blindness in the elderly. (Take AREDsII to reduce risk of cataracts)

Researchers at Israel’s Technion Institute have engineered an RNA molecule that repairs a damaged ubiquitin-proteasome system – a possible cause of Alzheimer’s disease. A faulty ubiquitin system leads to the accumulation of toxic proteins and amyloid plaque in Alzheimer’s patients. (Note Mito-C is designed to reduce misfolded proteins.)

The Lifespan newsletter is a good source of articles modelled on Nutrition Investigator, headlines about life extension with links to published articles.